Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Prepublished online as a Blood First Edition Paper on October 24, 2002; DOI 10.1182/blood-2002-06-1797.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2002-06-1797v1
101/5/1950    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yu, D.
Right arrow Articles by Thomas-Tikhonenko, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yu, D.
Right arrow Articles by Thomas-Tikhonenko, A.
Related Collections
Right arrow Hematopoiesis and Stem Cells
Right arrow Immunobiology
Right arrow Neoplasia
Right arrow Oncogenes and Tumor Suppressors
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Blood, 1 March 2003, Vol. 101, No. 5, pp. 1950-1955

NEOPLASIA

Oscillation between B-lymphoid and myeloid lineages in Myc-induced hematopoietic tumors following spontaneous silencing/reactivation of the EBF/Pax5 pathway

Duonan Yu, David Allman, Michael H. Goldschmidt, Michael L. Atchison, John G. Monroe, and Andrei Thomas-Tikhonenko

From the Departments of Pathobiology, Pathology and Laboratory Medicine, and Animal Biology, University of Pennsylvania, Philadelphia, PA.

B lymphomagenesis is an uncontrolled expansion of immature precursors that fail to complete their differentiation program. This failure could be at least partly explained by inappropriate expression of several oncogenic transcription factors, such as Pax5 and Myc. Both Pax5 and c-Myc are implicated in the pathogenesis of non-Hodgkin lymphomas. To address their role in lymphomagenesis, we analyzed B-cell lymphomas derived from p53-null bone marrow progenitors infected in vivo by a Myc-encoding retrovirus. All Myc-induced lymphomas invariably maintained expression of Pax5, which is thought to be incompatible with terminal differentiation. However, upon culturing in vitro, several cell lines spontaneously down-regulated Pax5 and its target genes CD19, N-Myc, and MB1. Unexpectedly, other B-cell markers (eg, CD45R) were also down-regulated, and markers of myeloid lineage (CD11b and F4/80 antigen) were acquired instead. Moreover, cells assumed the morphology reminiscent of myeloid cells. A pool of F4/80-positive cells as well as several single-cell clones were obtained and reinjected into syngeneic mice. Remarkably, pooled cells rapidly re-expressed Pax5 and formed tumors of relatively mature lymphoid phenotype, with surface immunoglobulins being abundantly expressed. Approximately half of tumorigenic single-cell clones also abandoned myeloid differentiation and gave rise to B lymphomas. However, when secondary lymphoma cells were returned to in vitro conditions, they once again switched to myeloid differentiation. This process could be curbed via enforced expression of retrovirally encoded Pax5. Our data demonstrate that some Myc target cells are bipotent B-lymphoid/myeloid progenitors with the astonishing capacity to undergo successive rounds of lineage switching.

© 2003 by The American Society of Hematology.
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
BloodHome page
A. L. Feldman, D. A. Arber, S. Pittaluga, A. Martinez, J. S. Burke, M. Raffeld, M. Camos, R. Warnke, and E. S. Jaffe
Clonally related follicular lymphomas and histiocytic/dendritic cell sarcomas: evidence for transdifferentiation of the follicular lymphoma clone
Blood, June 15, 2008; 111(12): 5433 - 5439.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
F. Mora-Lopez, E. Reales, J. A. Brieva, and A. Campos-Caro
Human BSAP and BLIMP1 conform an autoregulatory feedback loop
Blood, November 1, 2007; 110(9): 3150 - 3157.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
D. Yu, M. Carroll, and A. Thomas-Tikhonenko
p53 status dictates responses of B lymphomas to monotherapy with proteasome inhibitors
Blood, June 1, 2007; 109(11): 4936 - 4943.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. Hodawadekar, F. Wei, D. Yu, A. Thomas-Tikhonenko, and M. L. Atchison
Epigenetic Histone Modifications Do Not Control Ig{kappa} Locus Contraction and Intranuclear Localization in Cells with Dual B Cell-Macrophage Potential
J. Immunol., November 1, 2006; 177(9): 6165 - 6171.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
K. A. O'Donnell, D. Yu, K. I. Zeller, J.-w. Kim, F. Racke, A. Thomas-Tikhonenko, and C. V. Dang
Activation of Transferrin Receptor 1 by c-Myc Enhances Cellular Proliferation and Tumorigenesis.
Mol. Cell. Biol., March 1, 2006; 26(6): 2373 - 2386.
[Abstract] [Full Text] [PDF]


Home page
PediatricsHome page
S. Buonocore, A. L. Valente, D. Nightingale, J. Bogart, and A.-K. Souid
Histiocytic Sarcoma in a 3-Year-Old Male: A Case Report
Pediatrics, August 1, 2005; 116(2): e322 - e325.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. Yu, M. Dews, A. Park, J. W. Tobias, and A. Thomas-Tikhonenko
Inactivation of Myc in Murine Two-Hit B lymphomas Causes Dormancy with Elevated Levels of Interleukin 10 Receptor and CD20: Implications for Adjuvant Therapies
Cancer Res., June 15, 2005; 65(12): 5454 - 5461.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
M. S. Ricci, Z. Jin, M. Dews, D. Yu, A. Thomas-Tikhonenko, D. T. Dicker, and W. S. El-Deiry
Direct Repression of FLIP Expression by c-myc Is a Major Determinant of TRAIL Sensitivity
Mol. Cell. Biol., October 1, 2004; 24(19): 8541 - 8555.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
H. M. Bond, M. Mesuraca, E. Carbone, P. Bonelli, V. Agosti, N. Amodio, G. De Rosa, M. Di Nicola, A. M. Gianni, M. A. S. Moore, et al.
Early hematopoietic zinc finger protein (EHZF), the human homolog to mouse Evi3, is highly expressed in primitive human hematopoietic cells
Blood, March 15, 2004; 103(6): 2062 - 2070.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020